secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2025-04-04T23:59:59+00:00
Accession:  0000950170-25-051121
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara amends Pierre Fabre deal; transfers manufacturing, reduces milestones; eligible for up to $550M
--------------------------------------------------------------------------------

- Transferred all manufacturing responsibility for tab-cel to Pierre Fabre as of March 31, 2025; Pierre Fabre will manufacture and supply worldwide at its cost.
- Pierre Fabre assumes remediation costs for third-party facility to address FDA requests and support BLA resubmission for tab-cel.
- Atara reduced certain potential future regulatory and commercial milestone payments in exchange for the accelerated transfer and cost assumption.
- Atara now entitled to aggregate of up to $550M in potential milestones, including up to $40M regulatory milestones for FDA BLA approval; royalties unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017025051121/0000950170-25-051121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017025051121/atra-20250331.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-051121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer